Who is sponsoring NCT03621904?

NCT03621904 is sponsored by Radboud University Medical Center.

What drugs are being tested in NCT03621904?

Interventions in NCT03621904: Hormonal Antineoplastics.

What condition does NCT03621904 study?

NCT03621904 studies Endometrial Cancer Stage III, Endometrial Cancer Stage IV, Endometrial Cancer Recurrent.

Is NCT03621904 still recruiting?

NCT03621904 is currently recruiting now. Last updated 18 January 2023.

Last reviewed 2023-01-18 · How we verify

NCT03621904: PROMOTE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PROMOTE Study: Prediction of Response Of HorMOnal Treatment in Advanced and Recurrent Endometrial Cancer

Recruiting now Last updated 18 January 2023

What this trial tests

trial testing Hormonal Antineoplastics in Endometrial Cancer Stage III in 150 participants. Currently enrolling.

Timeline

15 October 2022

Primary endpoint
15 October 2026

1 September 2027

Quick facts

Lead sponsor	Radboud University Medical Center
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	150
Start date	15 October 2022
Primary completion	15 October 2026
Estimated completion	1 September 2027
Sites	1 location across Netherlands

Drugs / interventions tested

Hormonal Antineoplastics — full drug profile →

Conditions studied

Endometrial Cancer Stage III — all drugs for Endometrial Cancer Stage III →
Endometrial Cancer Stage IV — all drugs for Endometrial Cancer Stage IV →
Endometrial Cancer Recurrent — all drugs for Endometrial Cancer Recurrent →

Sponsor

Radboud University Medical Center

Who can join

Adults 18 to 110, female only, with Endometrial Cancer Stage III or Endometrial Cancer Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The PROMOTE study aims at optimising use of hormonal therapy in advanced stage and recurrent endometrial cancer analysing tumor tissue taken before start of hormonal therapy

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Hormonal Antineoplastics

Trials testing the same drug.

NCT05755581 — Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients · Phase 1 · unknown

Other Radboud University Medical Center trials

Trials by the same sponsor.

NCT07485569 — Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial · Phase 1 · not yet recruiting
NCT07514325 — MR-guided Adaptive Stereotactic Radiotherapy for Endometrial Cancer · NA · not yet recruiting
NCT07530263 — Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA) · Phase 1 · not yet recruiting
NCT07532577 — Intranasal Insulin to Prevent Intensive Care Unit Delirium · Phase 2, PHASE3 · not yet recruiting
NCT07504172 — Real-world Effectiveness and Dosing Patterns of Tirzepatide in People With Obesity · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03621904 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Radboud University Medical Center
Last refreshed: 18 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03621904.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing